Goodbye to hypos? 9 December 2014 Could hypoglycaemia soon be a thing of the past? A young scientist in the US has developed a non-insulin drug for people with type two diabetes that could help eliminate the risk of low-blood glucose hypos. Some people with type two diabetes use insulin to keep their blood glucose levels in check. If blood-glucose levels become too low, hypoglycaemia can occur and this can be life-threatening. To combat this, Arnab De, a scientist with a PhD in microbiology and immunology at Columbia University, developed a non-insulin drug in collaboration with fellow scientist Richard DiMarchi of Indiana University. “We find that there is a peptide hormone in the gut called GLP1 that increases the secretion of insulin only when the blood glucose is high,” Dr De said. “This effectively eliminates the risk of hypoglycemic shock. Another advantage is that GLP1 administration has been found to stimulate weight-loss. “The hormone offers the promise of revolutionising the treatment of type two diabetes and reduce obesity.” Read the article online at: http://www.diabetesqld.org.au/
Partners 1 June 2026 Does your CGM meet anzCGM standards? Advertisement When you live with diabetes, glucose readings influence everyday choices: from food and exercise to conversations with your healthcare... Continue Reading
Blog 1 June 2026 Rebuilding after the fall: Brett Findlay’s story of recovery and resilience Brett Findlay had just started a new job when he learnt he had type 1 diabetes. He figured he could manage diabetes by keeping his blood glucose levels consistently low. Then, one fateful day, he had a severe hypo. In this raw episode of Life on the Level, Brett talks about hypo unawareness, rebuilding after trauma, and the enduring strength of family. Continue Reading
Blog 1 June 2026 Life on the level podcast: returning for season 2 Life on the Level podcast is back with season 2. Hosted by young Aussies Isabella Magee and Sebastian Harris, this season explores what it's really like to live with type 1 diabetes; the challenges, the wins, and all the messy bits in between. Continue Reading